Ann: Change in substantial shareholder interest, page-3

At last the cat is out the bag and we can talk freely. The dir and our largest holder just brought out Paul Hopper. Problem solved and never to annoy us ever again, because the next milestone payments are only made on successful license of the drug and successful full completion of the phase IIb restriction trial . I will pop a bottle of port tonight to toast the team on successfully looking after the little guys by combining forces to remove Paul Hopper from the picture. Needle that was the story. A huge win for the little investors.